Healthcare Bullish Stocks: Agios Pharmaceuticals (NASDAQ:AGIO), Rockwell Medical (NASDAQ:RMTI), OHR Pharmaceutical (NASDAQ:OHRP), Emergent Biosolutions (NYSE:EBS)

Agios Pharmaceuticals Inc (NASDAQ:AGIO) SVP Glenn Goddard sold 17,468 shares of the stock on the open market in a transaction that occurred on Friday, March 7th. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 13.82 % in last session and finished the day at $ 45.45. Traded volume was 1,334,731 million shares in the last session and the average volume of the stock remained 283.01 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership is 0.40%.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. some stocks in the same industry looking equally good include Enzymotec Ltd. ( ENZY ), Rockwell Medical, Inc. (NASDAQ:RMTI) and William Demant Holding A/S ( WILYY ). Rockwell Medical Inc (NASDAQ:RMTI) rose 5.38 percent to $14.11 Friday on volume of 1.24million shares. The intra-day range of the stock was $13.20 to $14.15. Rockwell Medical Inc (NASDAQ:RMTI) has a market capitalization of $564.37million.

Cytosorbents Corporation (OTCBB:CTSO) share price has doubled, Mast Therapeutics, Inc. (NYSE MKT: MSTX) and OHR Pharmaceutical, Inc. (NASDAQ:OHRP) are both up approximately 85% and Accelerize New Media, Inc. (OTCBB:ACLZ) is up 20%.” OHR Pharmaceutical Inc (NASDAQ:OHRP)’s stock on Mar 7, 2014 reported a increase of 22.02% to the closing price of $17.73. Its fifty two weeks range is $4.11-$17.85. The total market capitalization recorded $354.07million. The overall volume in the last trading session was 1.16million shares. In its share capital, OHRP has 19.87million outstanding shares.

Biodel Inc. (NYSE:EBS), a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes, has signed a long-term manufacturing agreement with Cangene bioPharma Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc (NYSE:EBS) for development of its Glucagon Emergency Management (GEM) programme. On Friday, shares of Emergent Biosolutions Inc (NYSE:EBS) advanced 8.60% to close the day at $27.77. Company return on investment (ROI) is 3.20% and its monthly performance is recorded as 17.87%. Emergent Biosolutions Inc (NYSE:EBS) quarterly revenue growth is 23.20%.